Tigecycline-Containing Regimens and Multi Drug-Resistant Acinetobacter baumannii: A Systematic Review and Meta-Analysis.

IF 2.3 4区 医学 Q3 INFECTIOUS DISEASES
Fatemeh Sodeifian, Moein Zangiabadian, Erfan Arabpour, Naghmeh Kian, Fartous Yazarlou, Mehdi Goudarzi, Rosella Centis, Zahra Sadat Seghatoleslami, Mahdis Chahar Kameh, Bardia Danaei, Hossein Goudarzi, Mohammad Javad Nasiri, Giovanni Sotgiu, Giovanni Battista Migliori
{"title":"Tigecycline-Containing Regimens and Multi Drug-Resistant <i>Acinetobacter baumannii</i>: A Systematic Review and Meta-Analysis.","authors":"Fatemeh Sodeifian,&nbsp;Moein Zangiabadian,&nbsp;Erfan Arabpour,&nbsp;Naghmeh Kian,&nbsp;Fartous Yazarlou,&nbsp;Mehdi Goudarzi,&nbsp;Rosella Centis,&nbsp;Zahra Sadat Seghatoleslami,&nbsp;Mahdis Chahar Kameh,&nbsp;Bardia Danaei,&nbsp;Hossein Goudarzi,&nbsp;Mohammad Javad Nasiri,&nbsp;Giovanni Sotgiu,&nbsp;Giovanni Battista Migliori","doi":"10.1089/mdr.2022.0248","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Introduction:</i></b> The use of tigecycline (TG) for the treatment of <i>Acinetobacter baumannii</i> is controversial. In this systematic review and meta-analysis, we aimed to better explore the safety and efficacy of TG for the treatment of multi drug-resistant (MDR) Acinetobacter. <b><i>Methods:</i></b> We searched PubMed/MEDLINE, Scopus, Cochrane Central, and Web of Science to identify studies reporting the clinical and microbiological efficacy and safety of regimens containing TG in patients with drug susceptibility testing (DST)-confirmed MDR <i>A. baumannii</i>, published until December 30, 2022. Observational studies were included if they reported clinical and microbiological efficacy of TG-based regimens. The Newcastle-Ottawa Scale (NOS) and Joana Briggs Institute (JBI) critical appraisal tool were used to assess the quality of included studies. <b><i>Results:</i></b> There were 30 observational studies, of which 19 studies were cohort and 11 studies were single group studies. Pooled clinical response and failure rates in the TG-containing regimens group were 58.1 (95% confidence interval [CI] 49.2-66.6) and 40.2 (95% CI 31.1-50.0), respectively. The pooled microbiological response rate was 32.1 (95% CI 19.8-47.5), and the pooled all-cause mortality rate was 41.1 (95% CI 34.1-48.4). Pooled clinical response and failure rates in the colistin-based regimens group were 52.7 (42.7-62.5) and 43.1 (33.1-53.8), respectively. The pooled microbiological response rate was 42.9 (16.2-74.5), and the pooled all-cause mortality rate was 34.3 (26.1-43.5). <b><i>Conclusions:</i></b> According to our results, the efficacy of the TG-based regimen is the same as other antibiotics. However, our study showed a high mortality rate and a lower rate of microbiological eradication for TG compared with colistin-based regimen. Therefore, our study does not recommend it for the treatment of MDR <i>A. baumannii</i>. However, this was a prevalence meta-analysis of observational studies, and for better conclusion experimental studies are required.</p>","PeriodicalId":18701,"journal":{"name":"Microbial drug resistance","volume":"29 8","pages":"344-359"},"PeriodicalIF":2.3000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Microbial drug resistance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/mdr.2022.0248","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 1

Abstract

Introduction: The use of tigecycline (TG) for the treatment of Acinetobacter baumannii is controversial. In this systematic review and meta-analysis, we aimed to better explore the safety and efficacy of TG for the treatment of multi drug-resistant (MDR) Acinetobacter. Methods: We searched PubMed/MEDLINE, Scopus, Cochrane Central, and Web of Science to identify studies reporting the clinical and microbiological efficacy and safety of regimens containing TG in patients with drug susceptibility testing (DST)-confirmed MDR A. baumannii, published until December 30, 2022. Observational studies were included if they reported clinical and microbiological efficacy of TG-based regimens. The Newcastle-Ottawa Scale (NOS) and Joana Briggs Institute (JBI) critical appraisal tool were used to assess the quality of included studies. Results: There were 30 observational studies, of which 19 studies were cohort and 11 studies were single group studies. Pooled clinical response and failure rates in the TG-containing regimens group were 58.1 (95% confidence interval [CI] 49.2-66.6) and 40.2 (95% CI 31.1-50.0), respectively. The pooled microbiological response rate was 32.1 (95% CI 19.8-47.5), and the pooled all-cause mortality rate was 41.1 (95% CI 34.1-48.4). Pooled clinical response and failure rates in the colistin-based regimens group were 52.7 (42.7-62.5) and 43.1 (33.1-53.8), respectively. The pooled microbiological response rate was 42.9 (16.2-74.5), and the pooled all-cause mortality rate was 34.3 (26.1-43.5). Conclusions: According to our results, the efficacy of the TG-based regimen is the same as other antibiotics. However, our study showed a high mortality rate and a lower rate of microbiological eradication for TG compared with colistin-based regimen. Therefore, our study does not recommend it for the treatment of MDR A. baumannii. However, this was a prevalence meta-analysis of observational studies, and for better conclusion experimental studies are required.

含替加环素方案和多重耐药鲍曼不动杆菌:系统综述和荟萃分析。
前言:替加环素(TG)用于治疗鲍曼不动杆菌是有争议的。在本系统综述和荟萃分析中,我们旨在更好地探讨甘油三酯治疗多重耐药(MDR)不动杆菌的安全性和有效性。方法:我们检索PubMed/MEDLINE、Scopus、Cochrane Central和Web of Science,以确定截至2022年12月30日发表的关于含有TG的方案对药敏试验(DST)确诊的多药耐药鲍曼不动杆菌患者的临床和微生物学疗效和安全性的研究。如果观察性研究报告了基于tg的方案的临床和微生物功效,则纳入其中。采用纽卡斯尔渥太华量表(NOS)和乔安娜布里格斯研究所(JBI)关键评价工具评估纳入研究的质量。结果:共纳入观察性研究30项,其中队列研究19项,单组研究11项。含tg方案组的总临床缓解率和失败率分别为58.1(95%可信区间[CI] 49.2-66.6)和40.2 (95% CI 31.1-50.0)。合并微生物反应率为32.1 (95% CI 19.8-47.5),合并全因死亡率为41.1 (95% CI 34.1-48.4)。以粘菌素为基础的方案组的临床总有效率和失败率分别为52.7(42.7-62.5)和43.1(33.1-53.8)。合并微生物反应率为42.9(16.2-74.5),合并全因死亡率为34.3(26.1-43.5)。结论:根据我们的研究结果,以tg为基础的方案与其他抗生素的疗效相同。然而,我们的研究显示,与基于粘菌素的方案相比,TG的死亡率高,微生物根除率低。因此,我们的研究不推荐它用于治疗耐多药鲍曼杆菌。然而,这是一项观察性研究的患病率荟萃分析,为了得到更好的结论,还需要实验研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Microbial drug resistance
Microbial drug resistance 医学-传染病学
CiteScore
6.00
自引率
3.80%
发文量
118
审稿时长
6-12 weeks
期刊介绍: Microbial Drug Resistance (MDR) is an international, peer-reviewed journal that covers the global spread and threat of multi-drug resistant clones of major pathogens that are widely documented in hospitals and the scientific community. The Journal addresses the serious challenges of trying to decipher the molecular mechanisms of drug resistance. MDR provides a multidisciplinary forum for peer-reviewed original publications as well as topical reviews and special reports. MDR coverage includes: Molecular biology of resistance mechanisms Virulence genes and disease Molecular epidemiology Drug design Infection control.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信